JP2013231081A5 - - Google Patents

Download PDF

Info

Publication number
JP2013231081A5
JP2013231081A5 JP2013162201A JP2013162201A JP2013231081A5 JP 2013231081 A5 JP2013231081 A5 JP 2013231081A5 JP 2013162201 A JP2013162201 A JP 2013162201A JP 2013162201 A JP2013162201 A JP 2013162201A JP 2013231081 A5 JP2013231081 A5 JP 2013231081A5
Authority
JP
Japan
Prior art keywords
glycogenosis
glucosidase
type
human
medicament
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013162201A
Other languages
English (en)
Japanese (ja)
Other versions
JP5792774B2 (ja
JP2013231081A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2013231081A publication Critical patent/JP2013231081A/ja
Publication of JP2013231081A5 publication Critical patent/JP2013231081A5/ja
Application granted granted Critical
Publication of JP5792774B2 publication Critical patent/JP5792774B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2013162201A 2000-07-18 2013-08-05 Ii型糖原病の治療 Expired - Lifetime JP5792774B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21923700P 2000-07-18 2000-07-18
US60/219,237 2000-07-18

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2011173569A Division JP2012006953A (ja) 2000-07-18 2011-08-09 Ii型糖原病の治療

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014141336A Division JP2014185187A (ja) 2000-07-18 2014-07-09 Ii型糖原病の治療

Publications (3)

Publication Number Publication Date
JP2013231081A JP2013231081A (ja) 2013-11-14
JP2013231081A5 true JP2013231081A5 (enExample) 2014-08-21
JP5792774B2 JP5792774B2 (ja) 2015-10-14

Family

ID=22818451

Family Applications (10)

Application Number Title Priority Date Filing Date
JP2002511773A Expired - Lifetime JP5113312B2 (ja) 2000-07-18 2001-07-10 Ii型糖原病の治療
JP2007312804A Pending JP2008081507A (ja) 2000-07-18 2007-12-03 Ii型糖原病の治療
JP2011173569A Pending JP2012006953A (ja) 2000-07-18 2011-08-09 Ii型糖原病の治療
JP2013162201A Expired - Lifetime JP5792774B2 (ja) 2000-07-18 2013-08-05 Ii型糖原病の治療
JP2014141336A Pending JP2014185187A (ja) 2000-07-18 2014-07-09 Ii型糖原病の治療
JP2016005132A Expired - Lifetime JP6163216B2 (ja) 2000-07-18 2016-01-14 Ii型糖原病の治療
JP2017099515A Pending JP2017137357A (ja) 2000-07-18 2017-05-19 Ii型糖原病の治療
JP2017201250A Pending JP2018002749A (ja) 2000-07-18 2017-10-17 Ii型糖原病の治療
JP2018171154A Pending JP2018199721A (ja) 2000-07-18 2018-09-13 Ii型糖原病の治療
JP2019202851A Pending JP2020019822A (ja) 2000-07-18 2019-11-08 Ii型糖原病の治療

Family Applications Before (3)

Application Number Title Priority Date Filing Date
JP2002511773A Expired - Lifetime JP5113312B2 (ja) 2000-07-18 2001-07-10 Ii型糖原病の治療
JP2007312804A Pending JP2008081507A (ja) 2000-07-18 2007-12-03 Ii型糖原病の治療
JP2011173569A Pending JP2012006953A (ja) 2000-07-18 2011-08-09 Ii型糖原病の治療

Family Applications After (6)

Application Number Title Priority Date Filing Date
JP2014141336A Pending JP2014185187A (ja) 2000-07-18 2014-07-09 Ii型糖原病の治療
JP2016005132A Expired - Lifetime JP6163216B2 (ja) 2000-07-18 2016-01-14 Ii型糖原病の治療
JP2017099515A Pending JP2017137357A (ja) 2000-07-18 2017-05-19 Ii型糖原病の治療
JP2017201250A Pending JP2018002749A (ja) 2000-07-18 2017-10-17 Ii型糖原病の治療
JP2018171154A Pending JP2018199721A (ja) 2000-07-18 2018-09-13 Ii型糖原病の治療
JP2019202851A Pending JP2020019822A (ja) 2000-07-18 2019-11-08 Ii型糖原病の治療

Country Status (17)

Country Link
US (10) US7056712B2 (enExample)
EP (4) EP3108895B1 (enExample)
JP (10) JP5113312B2 (enExample)
AT (1) ATE355075T1 (enExample)
AU (3) AU2001271941B2 (enExample)
BR (1) BR0113006A (enExample)
CA (1) CA2416492C (enExample)
CY (2) CY1120977T1 (enExample)
DE (1) DE60126947T2 (enExample)
DK (5) DK1301201T3 (enExample)
ES (5) ES2599401T3 (enExample)
LT (3) LT3449934T (enExample)
MX (1) MXPA03000474A (enExample)
PT (5) PT2767291T (enExample)
SI (3) SI3449934T1 (enExample)
TW (1) TWI280882B (enExample)
WO (1) WO2002005841A1 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001271941B2 (en) * 2000-07-18 2007-03-01 Duke University Treatment of glycogen storage disease type II
US7629309B2 (en) 2002-05-29 2009-12-08 Zystor Therapeutics, Inc. Targeted therapeutic proteins
ES2300439T3 (es) * 2001-04-30 2008-06-16 Zystor Therapeutics , Inc. Reconocimiento subcelular de proteinas terapeuticas.
US7560424B2 (en) * 2001-04-30 2009-07-14 Zystor Therapeutics, Inc. Targeted therapeutic proteins
US20040005309A1 (en) * 2002-05-29 2004-01-08 Symbiontics, Inc. Targeted therapeutic proteins
US6981964B2 (en) 2001-05-22 2006-01-03 Boston Scientific Scimed, Inc. Draining bodily fluids with a stent
US20030072761A1 (en) * 2001-10-16 2003-04-17 Lebowitz Jonathan Methods and compositions for targeting proteins across the blood brain barrier
US6733536B1 (en) 2002-10-22 2004-05-11 Scimed Life Systems Male urethral stent device
WO2006002283A1 (en) * 2004-06-21 2006-01-05 Medtronic, Inc. Medical systems and methods for delivering compositions to cells
WO2004064750A2 (en) 2003-01-22 2004-08-05 Duke University Improved constructs for expressing lysosomal polypeptides
US7442372B2 (en) 2003-08-29 2008-10-28 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
US7129049B2 (en) * 2003-12-22 2006-10-31 Regents Of The University Of Minnesota Method of detecting equine glycogen storage disease IV
CN1922313B (zh) * 2004-02-10 2011-10-26 生物马林医药公司 酸性α-糖苷酶及其片段
US20050208090A1 (en) * 2004-03-18 2005-09-22 Medtronic, Inc. Methods and systems for treatment of neurological diseases of the central nervous system
WO2008063511A2 (en) * 2006-11-13 2008-05-29 Zystor Therapeutics, Inc. Methods for treating pompe disease
WO2009075815A1 (en) 2007-12-07 2009-06-18 Duke University Immunomodulating gene therapy
HRP20170698T1 (hr) 2008-05-07 2017-09-22 Biomarin Pharmaceutical Inc. Lizosomski usmjereni peptidi i njihove uporabe
HUE025212T2 (en) * 2008-07-08 2016-03-29 Univ Duke A method for treating glycogen storage disease
EP2475376B1 (en) 2009-06-17 2016-03-30 BioMarin Pharmaceutical Inc. Formulations for lysosomal enzymes
US8809282B2 (en) 2010-05-06 2014-08-19 Duke University Method of reducing titers of antibodies specific for a therapeutic agent
HK1220980A1 (zh) 2013-02-20 2017-05-19 Valerion Therapeutics, Llc 用於治疗庞贝氏症的方法和组合物
HK1222093A1 (zh) * 2013-05-15 2017-06-23 明尼苏达大学董事会 腺相关病毒介导的基因向中枢神经系统转移
MY186336A (en) 2014-09-30 2021-07-13 Amicus Therapeutics Inc Highly potent acid alpha-glucosidase with enhanced carbohydrates
WO2016178431A1 (ja) * 2015-05-07 2016-11-10 国立大学法人 東京大学 ポリイオンコンプレックス型ポリマーソームを用いたナノリアクタとその製造方法
US20180326021A1 (en) * 2015-08-31 2018-11-15 Duke University Methods and Compositions for the Treatment of Cytoplasmic Glycogen Storage Disorders
US10940125B2 (en) 2015-09-18 2021-03-09 Duke University Methods and compositions for the treatment of steatosis-associated disorders
CA3010205A1 (en) 2015-12-30 2017-07-06 Amicus Therapeutics, Inc. Augmented acid alpha-glucosidase for the treatment of pompe disease
IL301319A (en) 2016-03-30 2023-05-01 Amicus Therapeutics Inc Formulations that include recombinant acid alpha-glucosidase
MX2018011951A (es) 2016-03-30 2019-02-13 Amicus Therapeutics Inc Metodo para seleccionar proteinas recombinantes ricas en m6p.
SG11201808176TA (en) 2016-04-15 2018-10-30 The Trustees Of The Univ Of Pennsyvania Gene therapy for treating mucopolysaccharidosis type ii
EP3624831B1 (en) 2017-05-15 2023-03-29 Amicus Therapeutics, Inc. Recombinant human acid alpha-glucosidase
CA3076036A1 (en) 2017-09-22 2019-03-28 The Trustees Of The University Of Pennsylvania Gene therapy for treating mucopolysaccharidosis type ii
WO2020163480A1 (en) * 2019-02-05 2020-08-13 Amicus Therapeutics, Inc. Recombinant human acid alpha-glucosidase and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3063911A (en) * 1961-04-03 1962-11-13 Taisho Pharmaceutical Co Ltd Acid-stable digestive enzyme preparation and process of making same
US5464778A (en) 1989-03-08 1995-11-07 Board Of Regents Of The University Of Oklahoma Glycoprotein ligand for P-selectin and methods of use thereof
US5356804A (en) * 1990-10-24 1994-10-18 Mount Sinai School Of Medicine Of The City Of New York Cloning and expression of biologically active human α-galactosidase A
US6118045A (en) 1995-08-02 2000-09-12 Pharming B.V. Lysosomal proteins produced in the milk of transgenic animals
CN1300323A (zh) 1998-05-13 2001-06-20 加州大学洛杉矶分校港口研究和教育院 重组α-L-艾杜糖苷酸酶,其生产和纯化的方法以及治疗其缺乏导致的疾病的方法
AU3113700A (en) 1998-12-07 2000-06-26 Genzyme Corporation Treatment of pompe's disease
US6534300B1 (en) 1999-09-14 2003-03-18 Genzyme Glycobiology Research Institute, Inc. Methods for producing highly phosphorylated lysosomal hydrolases
AU2001271941B2 (en) * 2000-07-18 2007-03-01 Duke University Treatment of glycogen storage disease type II
US7629309B2 (en) 2002-05-29 2009-12-08 Zystor Therapeutics, Inc. Targeted therapeutic proteins
CN1922313B (zh) * 2004-02-10 2011-10-26 生物马林医药公司 酸性α-糖苷酶及其片段
US8470552B2 (en) 2009-10-12 2013-06-25 Keck Graduate Institute Strategy to reduce lactic acid production and control PH in animal cell culture

Similar Documents

Publication Publication Date Title
JP2013231081A5 (enExample)
JP2016056206A5 (enExample)
JP2011528896A5 (enExample)
EA201490377A1 (ru) Лечение рассеянного склероза комбинацией лаквинимода и глатирамера ацетата
NZ630790A (en) Il-15r alpha forms, cells expressing il-15r alpha forms, and therapeutic uses of il-15r alpha and il-15/il-15r alpha complexes
JP2013067645A5 (enExample)
JP2012102122A5 (enExample)
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
JP2015521607A5 (enExample)
PH12012501364A1 (en) Antibody formulation and therapeutic regimens
EA033400B1 (ru) Антитело против cd3 и его применение
JP2013505205A5 (enExample)
JP2011528897A5 (enExample)
NZ702801A (en) Treatment of sanfilippo syndrome type b
JP2016539156A5 (enExample)
NZ608502A (en) Polypeptides that bind to human complement component c5
PH12014502447A1 (en) Use of high dose laquinimod for treating multiple sclerosis
JP2016514132A5 (enExample)
BR112015010396A2 (pt) terapia de combinação
PH12014501620A1 (en) Compositions and methods for the treatment of hepatic diseases and disorders
JP2014513722A5 (enExample)
JP2014532722A5 (enExample)
RU2015116264A (ru) Композиции и способы лечения сердечной недостаточности у пациентов с диабетом
WO2016109823A8 (en) Treatment of pediatric growth hormone deficiency with human growth hormone analogues
JP2013100370A5 (enExample)